#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	4778	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2708	523.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1803	1803	C	713	C,G	588,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7456	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4051	550.6	0	.	n	.	0	T695C	SNP	695	695	T	1299	1299	C	529	C	443	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7456	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4051	550.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1941	1941	A	654	A,G,C	572,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7456	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4051	550.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2575	2575	C	687	C	594	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7456	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4051	550.6	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3201	3201	T	637	T,A	545,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7456	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4051	550.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2649	2649	A	687	A	592	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	826	folP	852	852	100.0	folP.l15.c4.ctg.1	1946	126.7	1	SNP	p	R228S	1	.	.	682	684	AGC	1176	1178	AGC	175;177;177	A;G;C,T	157;160;158,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1624	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3875	125.6	1	SNP	p	S91F	0	.	.	271	273	TCC	803	805	TCC	148;149;150	T,A;C,T;CG,C	130,1;129,1;129,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1624	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3875	125.6	1	SNP	p	D95G	0	.	.	283	285	GAC	815	817	GAC	149;148;148	G;A;C	129;127;127	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1624	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3875	125.6	1	SNP	p	D95N	0	.	.	283	285	GAC	815	817	GAC	149;148;148	G;A;C	129;127;127	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	750	mtrR	633	633	99.21	mtrR.l6.c30.ctg.1	1687	132.7	0	.	p	.	0	A39T	NONSYN	115	117	GCC	643	645	ACC	197;198;198	A;C;C,A	172;174;175,1	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	750	mtrR	633	633	99.21	mtrR.l6.c30.ctg.1	1687	132.7	0	.	p	.	0	R44H	NONSYN	130	132	CGC	658	660	CAC	204;203;204	C;A;C	169;174;176	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	750	mtrR	633	633	99.21	mtrR.l6.c30.ctg.1	1687	132.7	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	841	843	CAC	216;214;217	C;A;C	187;186;192	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	750	mtrR	633	633	99.21	mtrR.l6.c30.ctg.1	1687	132.7	1	SNP	p	G45D	0	.	.	133	135	GGC	661	663	GGC	205;205;204	G;G;C	174;174;177	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	500	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1424	105.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1624	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3332	145.8	1	SNP	p	D86N	0	.	.	256	258	GAC	806	808	GAC	197;196;197	G;A,C;C	159;152,2;159	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1624	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3332	145.8	1	SNP	p	S87W	0	.	.	259	261	AGT	809	811	AGT	196;196;195	A;G;T	155;160;156	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1624	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3332	145.8	1	SNP	p	S87I	0	.	.	259	261	AGT	809	811	AGT	196;196;195	A;G;T	155;160;156	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1624	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3332	145.8	1	SNP	p	S87R	0	.	.	259	261	AGT	809	811	AGT	196;196;195	A;G;T	155;160;156	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1624	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3332	145.8	1	SNP	p	S88P	0	.	.	262	264	TCC	812	814	TCC	195;193;192	T;C;C	159;154;160	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1416	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3161	134.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1796	1798	GGC	194;196;195	G,T;G,A;C	169,1;167,1;166	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	1074	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	111.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1528	1530	GCA	140;139;139	G,T;C;A,C	124,1;123;121,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1074	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	111.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1531	1533	ATC	139;139;140	A;T;C,G	122;119;122,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1074	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	111.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1543	1545	GTG	135;135;135	G,A;T,C;G,C,A	119,1;114,1;114,1,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1074	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	111.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1543	1545	GTG	135;135;135	G,A;T,C;G,C,A	119,1;114,1;114,1,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1074	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	111.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2047	2049	ACC	115;115;115	A,C;C,A;C	97,1;93,1;96	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1074	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	111.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2101	2103	GCG	117;118;115	G,T;C,A,G;G,C	97,1;84,1,1;84,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1074	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	111.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2101	2103	GCG	117;118;115	G,T;C,A,G;G,C	97,1;84,1,1;84,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1074	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	111.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2224	2226	GGC	121;122;123	G,C;G,T;C	101,2;104,1;105	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1074	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	111.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2233	2235	GGC	124;123;122	G,A,C;G;C,T	99,1,1;102;102,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1074	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	111.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2251	2253	CCG	123;123;123	C;C;G	98;104;97	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1738	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3625	143.5	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1868	1870	CTG	173;173;174	C,G,T;T;G,T,C	145,2,1;144;149,1,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	832	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2419	103.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	908	908	C	137	C	117	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	864	porB1b	1035	1035	95.63	porB1b.l6.c17.ctg.1	2054	124.4	0	.	p	.	0	E48G	NONSYN	142	144	GAA	729	731	GGA	174;174;175	G,C;G;A	147,1;150;151	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	864	porB1b	1035	1035	95.63	porB1b.l6.c17.ctg.1	2054	124.4	0	.	p	.	0	G50N	NONSYN	148	150	GGC	735	737	AAC	175;174;174	A;A,C;C	153;156,1;149	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	864	porB1b	1035	1035	95.63	porB1b.l6.c17.ctg.1	2054	124.4	0	.	p	.	0	F135L	NONSYN	403	405	TTT	990	992	CTT	178;176;176	C;T;T,G	155;150;150,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	864	porB1b	1035	1035	95.63	porB1b.l6.c17.ctg.1	2054	124.4	0	.	p	.	0	R143G	NONSYN	427	429	AGA	1014	1016	GGA	184;184;182	G;G;A	163;161;160	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	864	porB1b	1035	1035	95.63	porB1b.l6.c17.ctg.1	2054	124.4	0	.	p	.	0	D171G	NONSYN	511	513	GAT	1098	1100	GGT	167;166;166	G;G,T;T	152;150,1;150	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	864	porB1b	1035	1035	95.63	porB1b.l6.c17.ctg.1	2054	124.4	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1152	1154	AGC	178;177;177	A;G;C	152;148;152	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	864	porB1b	1035	1035	95.63	porB1b.l6.c17.ctg.1	2054	124.4	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1218	1218	T	171	T	142	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	864	porB1b	1035	1035	95.63	porB1b.l6.c17.ctg.1	2054	124.4	1	SNP	p	G120K	0	.	.	358	360	GGT	945	947	GGT	190;189;187	G;G;T,A,G	157;152;155,1,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	864	porB1b	1035	1035	95.63	porB1b.l6.c17.ctg.1	2054	124.4	1	SNP	p	A121N	0	.	.	361	363	GCC	948	950	GCC	185;185;186	G;C;C	148;152;155	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	864	porB1b	1035	1035	95.63	porB1b.l6.c17.ctg.1	2054	124.4	1	SNP	p	A121D	0	.	.	361	363	GCC	948	950	GCC	185;185;186	G;C;C	148;152;155	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	3134	rpoB	4179	4179	100.0	rpoB.l6.c17.ctg.1	5185	180.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2171	2173	AAT	174;173;172	A;A,G,T;T,G	149;148,1,1;143,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	486	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1456	100.1	1	SNP	p	V57M	1	.	.	169	171	ATG	811	813	ATG	188;187;189	A;T;G,T	160;160;159,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
